Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 11/20 | 0.40 |
| ▸ | OXTR | P30559 | 7/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017369 | 0.93 | RAB9A (0.36) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3006471 | 0.93 | RAB9A (0.41) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3014356 | 0.91 | RAB9A (0.41) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3016548 | 0.91 | KMT2A (0.38) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3002254 | 0.91 | SMN1; SMN2 (0.42) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3016039 | 0.91 | MAPT (0.46) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A | |
| SCHEMBL3010946 | 0.90 | MAPT (0.41) | SMN1; SMN2MAPTTP53ALDH1A1LMNA | |
| SCHEMBL3015039 | 0.89 | GBA1 (0.42) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL3013175 | 0.89 | HRH3 (0.34) | SMN1; SMN2TP53ALDH1A1LMNA | |
| SCHEMBL3014690 | 0.89 | HSD11B1 (0.41) | RAB9ASMN1; SMN2AVPR1BOXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | RAB9A 2943/4885SMN1; SMN2 1/4885AVPR1B 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.